Thomas O'Brien, MD
Advanced Heart Failure and Transplant Cardiology · Liberty Township, OHNPI 1003844366
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,350 of the $50,366 with a category attached, or 84.1%. AstraZeneca accounts for 63.9% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $16,675 and has fallen 99.7% since, to $43 in 2025.
Across 79 payments — averaging $637.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$32K
- Novartis$14K
- Nuwellis, Inc.$2K
- Philips North America LLC$2K
- Cvrx, Inc.$153
- Abiomed$150
- plus $634 from 10 others
What the payments were for
- Consulting fees$4501%
- Speaking & faculty fees$42,35084%
- Travel & lodging$4,5649%
- Food & beverage$2,9926%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $32,200 |
| Novartis | 10 | $13,704 |
| Nuwellis, Inc. | 6 | $1,875 |
| Philips North America LLC | 4 | $1,649 |
| Cvrx, Inc. | 1 | $153 |
| Abiomed | 1 | $150 |
| Abbott | 1 | $149 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $130 |
| Janssen Scientific Affairs, LLC | 1 | $130 |
| Lundbeck LLC | 1 | $77 |
| Medtronic | 2 | $59 |
| Atricure, Inc. | 1 | $27 |
| Merck | 1 | $22 |
| Chiesi USA, Inc. | 1 | $16 |
| Pfizer | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$31,695
- ENTRESTO$13,659
- AQUADEX SMARTFLOW CONSOLE$1,382
- (9547) IGT Systems Undivided$893
- IGT Systems Und$755
- Aquadex$450
- Barostim Neo System$153
- Impella$150
- CARDIOMEMS$149
- Tremfya$130
- LifeVest$100
How this compares
$50,366 in reported general payments places this provider in the 85th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 514 | $574,519 |
| EntrestoSacubitril/Valsartan | 229 | $273,170 |
| XareltoRivaroxaban | 144 | $178,063 |
| FarxigaDapagliflozin Propanediol | 189 | $169,798 |
| JardianceEmpagliflozin | 90 | $101,905 |
| Repatha SureclickEvolocumab | 79 | $76,027 |
| Repatha SyringeEvolocumab | 38 | $25,424 |
| BrilintaTicagrelor | 32 | $21,509 |
| WegovySemaglutide | 13 | $18,786 |
| OzempicSemaglutide | 14 | $18,185 |
| Bosentan | 11 | $13,690 |
| Praluent PenAlirocumab | 19 | $11,637 |
| DapagliflozinDapagliflozin Propanediol | 22 | $11,046 |
| Metoprolol Succinate | 700 | $8,880 |
| Ranolazine ErRanolazine | 80 | $8,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $574,519514 claims |
| NovartisEntresto | $13,704 | $273,170229 claims |
| AstraZenecaFarxiga, Brilinta | $32,200 | $191,307221 claims |
| Johnson & JohnsonXarelto | $11 | $178,063144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Liberty Township
- William AbrahamColumbus$802K
- Rami KahwashColumbus$379K
- Eugene ChungCincinnati$297K
- Kenneth VarianAkron$170K
- Ankit BhatiaCincinnati$141K
- Rachel GarciaCincinnati$104K
- Sateesh KesariCincinnati$101K
- Sitaramesh EmaniCincinnati$87K
- Gregory EgnaczykCincinnati$62K
- Imad HaririToledo$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.